In the past week, CTIC stock has gone up by 0.78%, with a monthly gain of 79.28% and a quarterly surge of 63.64%. The volatility ratio for the week is 0.39%, and the volatility levels for the last 30 days are 2.42% for CTI BioPharma Corp. The simple moving average for the last 20 days is 29.99% for CTIC stock, with a simple moving average of 61.87% for the last 200 days.
Is It Worth Investing in CTI BioPharma Corp. (NASDAQ: CTIC) Right Now?
Moreover, the 36-month beta value for CTIC is 0.75.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The average price recommended by analysts for CTI BioPharma Corp. (CTIC) is $10.30, which is $1.49 above the current market price. The public float for CTIC is 125.91M and currently, short sellers hold a 9.66% of that float. On May 25, 2023, CTIC’s average trading volume was 5.92M shares.
CTIC) stock’s latest price update
CTI BioPharma Corp. (NASDAQ: CTIC) has seen a rise in its stock price by 0.11 in relation to its previous close of 8.99. However, the company has experienced a 0.78% gain in its stock price over the last five trading sessions.
CTIC Trading at 65.18% from the 50-Day Moving Average
After a stumble in the market that brought CTIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.55% of loss for the given period.
Volatility was left at 2.42%, however, over the last 30 days, the volatility rate increased by 0.39%, as shares surge +82.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +97.80% upper at present.
During the last 5 trading sessions, CTIC rose by +0.78%, which changed the moving average for the period of 200-days by +27.48% in comparison to the 20-day moving average, which settled at $7.13. In addition, CTI BioPharma Corp. saw 49.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTIC starting from Fong James K, who sale 100,000 shares at the price of $6.00 back on Jan 24. After this action, Fong James K now owns 3,565 shares of CTI BioPharma Corp., valued at $600,000 using the latest closing price.
Craig Adam R, the President and CEO of CTI BioPharma Corp., sale 85,317 shares at $6.00 during a trade that took place back on Jan 24, which means that Craig Adam R is holding 29,440 shares at $511,923 based on the most recent closing price.
Stock Fundamentals for CTIC
Current profitability levels for the company are sitting at:
- -128.82 for the present operating margin
- +93.12 for the gross margin
The net margin for CTI BioPharma Corp. stands at -172.37. The total capital return value is set at -87.90, while invested capital returns managed to touch -367.75. Equity return is now at value 425.90, with -55.80 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 16.19, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 7.01 and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.23.
Conclusion
To wrap up, the performance of CTI BioPharma Corp. (CTIC) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
